정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 723 | Active, not recruiting | Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine | COVID-19 | Drug: BCG Vaccine Drug: Placebo |
Phase 3 | UMC Utrecht, Radboud University | OTHER | 1500 | All | 18 Years | Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands Radboud UMC, Nijmegen, Gelderland, Netherlands Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands University Medical Center Utrecht, Utrecht, Netherlands |
| 722 | Recruiting | Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care | COVID-19 Respiratory Infection | Drug: Topotecan | Phase 1 | National University Hospital, Singapore, Christian Medical College, Vellore, India | OTHER | 24 | All | 21 Years ~ 99 Years | Christian Medical College, Vellore, Tamil Nadu, India |
| 721 | Recruiting | Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER) | Covid19 | Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Other: Placebo |
Phase 1 | Longeveron Inc. | INDUSTRY | 70 | All | 18 Years | Miami VA Healthcare System, Miami, Florida, United States University of Maryland Medical Center, Baltimore, Maryland, United States Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States |
| 720 | Active, not recruiting | REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia | ARDS | Biological: CK0802 Drug: Placebo |
Phase 1 | Cellenkos, Inc. | INDUSTRY | 45 | All | 18 Years | Johns Hopkins Hospital, Baltimore, Maryland, United States Columbia University, New York, New York, United States University of North Carolina, Chapel Hill, North Carolina, United States Wake Forest University, Winston-Salem, North Carolina, United States Baylor College of Medicine, St Luke's Hospital, Houston, Texas, United States |
| 719 | Not yet recruiting | Relationship Between Biological Profiles and Clinical Evolutions Within the Same Cluster COVID-19 (COVIDCOLLECT) | Contact Case | Biological: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine | Not Applicable | University Hospital, Clermont-Ferrand | OTHER | 100 | All | CHU de Clermont-Ferrand, Clermont-Ferrand, France | |
| 718 | Completed | Remdesivir Efficacy in Coronavirus Disease | COVID | Drug: Remdesivir Other: Standard of care treatment |
Phase 3 | Tanta University | OTHER | 200 | All | Tanta university hospital, Assuit University, Ainshams University, Tanta, Egypt | |
| 717 | Completed | Remdesivir Efficacy In Management Of COVID-19 Patients | Covid19 | Drug: Remdesivir Drug: Standard of care_1 Drug: Standard of care_2 |
Phase 3 | Ain Shams University | OTHER | 77 | All | 18 Years ~ 80 Years | Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt |